Astellas Enters into a Research Collaboration and License Agreement with Elpiscience to Develop Bispecific Macrophage Engagers to Treat Cancer
Shots:
- Astellas has signed a research collaboration and license agreement with Elpiscience Biopharma to jointly conduct the early-stage research for ES019 & another program
- Additionally, Astellas also received the rights to add up to 2 additional programs to be included in the collaboration and if the option exercised, will also receive the exclusive right to further research, develop, manufacture & commercialize the products for each program
- Under the terms of the agreement, Elpiscience will receive an up front payment & license option fee of $37M along with research fundings to advance the programs. Upon option exercise by Astellas, Elpiscience will be eligible to receive more than ~$1.7B in development, regulatory & commercial milestones plus double-digit percent royalty
Ref: Astellas | Image: Astellas
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
